UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission
File Number
(Exact name of registrant as specified in its charter)
(State or other jurisdiction | (IRS Employer | |
of incorporation or organization) | Identification No.) |
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbols | Name of each exchange on which registered | ||
The |
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2)
has been subject to such filing requirements for the past 90 days:
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files);
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☒ | Smaller reporting company | ||
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
shares of common stock, $0.01 par value, were outstanding at November 8, 2023.
SINTX Technologies, Inc.
Table of Contents
2 |
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
SINTX Technologies, Inc.
Condensed Consolidated Balance Sheets - Unaudited
(in thousands, except share and per share data)
September 30, 2023 | December 31, 2022 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | $ | ||||||
Account and other receivables, net of allowance | ||||||||
Prepaid expenses and other current assets | ||||||||
Inventories | ||||||||
Other current assets | ||||||||
Total current assets | ||||||||
Inventories, net | ||||||||
Property and equipment, net | ||||||||
Intangible assets, net | ||||||||
Operating lease right of use asset | ||||||||
Other long-term assets | ||||||||
Total assets | $ | $ | ||||||
Liabilities and Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | $ | ||||||
Accrued liabilities | ||||||||
Current portion of long-term debt | ||||||||
Derivative liabilities | ||||||||
Current portion of operating lease liability | ||||||||
Other current liabilities | ||||||||
Total current liabilities | ||||||||
Operating lease liability, net of current portion | ||||||||
Long term debt, net of current portion | ||||||||
Other long-term liabilities | ||||||||
Total liabilities | ||||||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Convertible preferred stock Series B, $ par value, total shares authorized inclusive of all series of preferred; shares issued and outstanding as of September 30, 2023 and December 31, 2022. | ||||||||
Convertible preferred stock Series C, $ par value, total shares authorized inclusive of all series of preferred; shares issued and outstanding as of September 30, 2023 and December 31, 2022. | ||||||||
Convertible preferred stock Series D, $ par value, total shares authorized inclusive of all series of preferred; and shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively. | ||||||||
Convertible preferred stock Series E, $ par value, total shares authorized inclusive of all series of preferred; and share issued and outstanding as of September 30, 2023 and December 31, 2022, respectively. | ||||||||
Common stock, $ par value, shares authorized; and shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively. | ||||||||
Additional paid-in capital | ||||||||
Accumulated deficit | ( | ) | ( | ) | ||||
Total stockholders’ equity | ||||||||
Total liabilities and stockholders’ equity | $ | $ |
The condensed consolidated balance sheet as of December 31, 2022, has been prepared using information from the audited consolidated balance sheet as of that date.
The accompanying notes are an integral part of these condensed consolidated financial statements.
3 |
SINTX Technologies, Inc.
Condensed Consolidated Statements of Operations - Unaudited
(in thousands, except share data)
Three Months Ended September 30, | Nine months Ended September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Product revenue | $ | $ | $ | $ | ||||||||||||
Grant and contract revenue | ||||||||||||||||
Total revenue | ||||||||||||||||
Costs of revenue | ||||||||||||||||
Gross profit | ||||||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | ||||||||||||||||
General and administrative | ||||||||||||||||
Sales and marketing | ||||||||||||||||
Grant and contract expenses | ||||||||||||||||
Total operating expenses | ||||||||||||||||
Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Other income (expenses): | ||||||||||||||||
Interest expense | ( | ) | ( | ) | ( | ) | ||||||||||
Interest income | ||||||||||||||||
Gain (loss) on disposal of assets | ( | ) | ||||||||||||||
Change in fair value of derivative liabilities | ||||||||||||||||
Offering costs of derivative liabilities | ( | ) | ||||||||||||||
Other income, net | ||||||||||||||||
Total other income (expense), net | ||||||||||||||||
Net loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Provision for income taxes | ||||||||||||||||
Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Deemed dividend related to convertible preferred stock | ( | ) | ||||||||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
Net loss per share – basic and diluted | ||||||||||||||||
Basic – net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
Basic – deemed dividend on conversion of preferred stock | ( | ) | ||||||||||||||
Basic – attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
Diluted – net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
Diluted - deemed dividend on conversion of preferred stock | ( | ) | ||||||||||||||
Diluted – attributable to common stockholders | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | ||||||||||||||||
Diluted |
The accompanying notes are an integral part of these condensed consolidated financial statements.
4 |
SINTX Technologies, Inc.
Condensed Consolidated Statements of Stockholders’ Equity - Unaudited
(in thousands, except share and per share data)
Preferred Stock | Common Stock | Paid-In | Accumulated | Total | ||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||
Balance as of December 31, 2021 | ( | ) | ||||||||||||||||||||||||||
Stock based compensation | - | |||||||||||||||||||||||||||
Net loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
Balance as of March 31, 2022 | ( | ) | ||||||||||||||||||||||||||
Stock based compensation | - | |||||||||||||||||||||||||||
Acquisition of subsidiary | - | - | ||||||||||||||||||||||||||
Net loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
Balance as of June 30, 2022 | ( | ) | ||||||||||||||||||||||||||
Stock based compensation | - | |||||||||||||||||||||||||||
Common stock issued on conversion of preferred stock | ( | ) | ||||||||||||||||||||||||||
Net loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
Balance as of September 30, 2022 | $ | $ | $ | $ | ( | ) | $ |
Preferred Stock | Common Stock | Paid-In | Accumulated | Total | ||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||
Balance as of December 31, 2022 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||
Stock based compensation | - | |||||||||||||||||||||||||||
Common stock issued for cash, net of cash fees | - | |||||||||||||||||||||||||||
Prefunded warrants issued for cash, net of cash fees | - | - | ||||||||||||||||||||||||||
Extinguishment of derivative liability upon exercise of warrant | - | - | ||||||||||||||||||||||||||
Issuance of common stock from the exercise of prefunded warrants for cash | - | ( | ) | |||||||||||||||||||||||||
Issuance of common stock from the cashless exercise of warrants | - | ( | ) | |||||||||||||||||||||||||
Redemption of preferred stock | ( | ) | - | ( | ) | ( | ) | |||||||||||||||||||||
Issuance of agent warrants | - | - | ||||||||||||||||||||||||||
Round up shares issued in reverse split | - | |||||||||||||||||||||||||||
Net loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
Balance as of March 31, 2023 | ( | ) | ||||||||||||||||||||||||||
Stock based compensation | - | |||||||||||||||||||||||||||
Extinguishment of derivative liability upon exercise of warrant | - | - | ||||||||||||||||||||||||||
Issuance of common stock from the cashless exercise of warrants | - | ( | ) | |||||||||||||||||||||||||
Issuance of common stock from the conversion of preferred stock | ( | ) | ||||||||||||||||||||||||||
Deemed dividend related to the conversion of preferred stock | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
Deemed dividend related to the conversion of preferred stock | - | - | ||||||||||||||||||||||||||
Net loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
Balance as of June 30, 2023 | ( | ) | ||||||||||||||||||||||||||
Stock based compensation | - | |||||||||||||||||||||||||||
Net loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
Balance as of September 30, 2023 | $ | $ | $ | $ | ( | ) | $ |
The accompanying notes are an integral part of these condensed consolidated financial statements.
5 |
SINTX Technologies, Inc.
Condensed Consolidated Statements of Cash Flows - Unaudited
(in thousands)
Nine months Ended September 30, | ||||||||
2023 | 2022 | |||||||
Cash Flow From Operating Activities | ||||||||
Net loss | $ | ( | ) | $ | ( | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation expense | ||||||||
Amortization of right of use asset | ||||||||
Amortization of intangible assets | ||||||||
Stock based compensation | ||||||||
Change in fair value of derivative liabilities | ( | ) | ( | ) | ||||
Gain on disposal of property and equipment | ( | ) | ||||||
Bad debt expense | ( | ) | ||||||
Changes in operating assets and liabilities: | ||||||||
Trade accounts receivable | ||||||||
Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
Inventories | ( | ) | ( | ) | ||||
Accounts payable and accrued liabilities | ||||||||
Other liabilities | ( | ) | ( | ) | ||||
Payments on operating lease liability | ( | ) | ( | ) | ||||
Net cash used in operating activities | ( | ) | ( | ) | ||||
Cash Flows From Investing Activities | ||||||||
Purchase of property and equipment | ( | ) | ( | ) | ||||
Proceeds from the sale of property and equipment | ||||||||
Cash acquired in acquisition (see Note 2) | ||||||||
Net cash used in investing activities | ( | ) | ( | ) | ||||
Cash Flows From Financing Activities | ||||||||
Proceeds from issuance of warrant derivative liabilities | ||||||||
Proceeds from issuance of
common stock and prefunded warrants, net of cash fees of $ | ||||||||
Redemption of preferred stock Series E | ( | ) | ||||||
Payments on debt | ( | ) | ( | ) | ||||
Net cash provided by (used in) financing activities | ( | ) | ||||||
Net increase (decrease) in cash and cash equivalents | ( | ) | ( | ) | ||||
Cash and cash equivalents at beginning of period | ||||||||
Cash and cash equivalents at end of period | $ | $ | ||||||
Noncash Investing and Financing Activities | ||||||||
Extinguishment of derivative liabilities through exercise of warrants | $ | $ | ||||||
Right of use asset for new lease liability | ||||||||
Right of use asset for amended lease liability | ( | ) | ||||||
Par value of common stock upon cashless exercise of warrants | ||||||||
Par value of common stock upon exercise of prefunded warrants | ||||||||
Acquisition of subsidiary through assumption of debt | ||||||||
Reduction of debt through increase in accrued liabilities | ||||||||
Supplemental Cash Flow Information | ||||||||
Cash paid for interest | $ | $ |
The accompanying notes are an integral part of these condensed consolidated financial statements.
6 |
SINTX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Organization and Summary of Significant Accounting Policies
The condensed consolidated financial statements include the accounts of SINTX Technologies, Inc. (“SINTX”) and its wholly-owned subsidiaries, SINTX Armor, Inc. (“SINTX Armor”) and Technology Assessment and Transfer, Inc. (TA&T), which are collectively referred to as “we” or “the Company”. SINTX is an advanced ceramics company formed in December 1996 (and was previously known as Amedica Corporation) and is focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. We have grown from focusing primarily on the research, development and commercialization of medical devices manufactured with silicon nitride to becoming an advanced ceramics company engaged in diverse fields, including biomedical, technical and antipathogenic applications. This diversification enables us to focus on our core competencies, which are the manufacturing, research, and development of products comprised from advanced ceramic materials for external partners. We seek to connect with new customers, partners and manufacturers to help them realize the goal of leveraging our expertise in advanced ceramics to create new, innovative products across these sectors. The Company presently manufactures ceramic powders and components in its Salt Lake City and Maryland facilities. The SINTX Salt Lake City facility is FDA and ANVISA registered, ISO 13485:2016 certified, and ASD9100D certified. The Company’s products are primarily sold in the United States.
The Company is focused on building revenue generating opportunities in three business industries – biomedical, technical (including aerospace and armor), and antipathogenic – thereby connecting with current and new customers, partners and manufacturers to help realize the goal of leveraging expertise in high-tech ceramics to create new, innovative opportunities across these sectors. We expect our continued investment in research and development to provide additional revenue opportunities.
SINTX believes it is the first and only manufacturer to use silicon nitride in medical applications primarily focused on spine fusion therapies. Since then, we have developed other applications for our silicon nitride technology as well as utilized our expertise in the use of ceramic materials in other applications. In July 2021, the Company acquired the equipment and obtained certain proprietary know-how rights it is now using to develop, manufacture, and commercialize protective armor from boron carbide and a composite material of silicon carbide and boron carbide for military, law enforcement and civilian uses. The protective armor operations are housed in SINTX Armor. In June 2022, the Company acquired TA&T, a nearly 40-year-old business with a mission to transition advanced materials and process technologies from a laboratory environment to commercial products and services.
On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical, a Dallas, Texas-based privately held medical device manufacturer. As a result of the sale, CTL Medical became the exclusive owner of the Company’s portfolio of metal and silicon nitride spine products, as well as access to future silicon nitride spine technologies developed by the Company. The Company’s name, Amedica, was also transferred to CTL Medical, which is now CTL Amedica. The Company serves as CTL’s exclusive OEM provider of silicon nitride spine products. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology including silicon nitride remains with the Company.
On October 30, 2018, the Company amended its Certificate of Incorporation with the State of Delaware to change its corporate name to SINTX Technologies, Inc. The Company also changed its trading symbol on the NASDAQ Capital Market to “SINT”.
The Company’s new corporate brand reflects both the Company’s core competence in the science and production of silicon nitride ceramics and other ceramics, as well as encouraging prospects for the future, as an OEM supplier of spine implants to CTL Amedica, and multiple opportunities outside of spine.
7 |
Basis of Presentation
These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company.
SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 29, 2023. The results of operations for the nine months ended September 30, 2023, are not necessarily indicative of the results to be expected for the year ending December 31, 2023. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2022.
Reverse Stock Split
On
December 20, 2022, the Company effected a
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2023, the most significant estimate relates to derivative liabilities relating to common stock warrants.
Liquidity and Capital Resources
The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.
For
the nine months ended September 30, 2023, and 2022, the Company incurred a net loss of $
The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our advanced ceramic materials are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications. The Company has also acquired equipment and certain proprietary know-how for the purpose of developing, manufacturing and commercializing armored plates made from boron carbide and a composite of boron carbide and silicon carbide for military, law enforcement and other civilian uses. The addition of TA&T also expands the Company’s opportunity for revenue growth.
8 |
The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014.
On
February 25, 2021, the Company entered into an Equity Distribution Agreement (as amended, the “2021 Distribution Agreement”)
with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of the Company’s common
stock having an aggregate offering price of up to $
On
October 17, 2022, the Company closed on the sale of
On
February 10, 2023, the Company closed on a public offering of
If the Company seeks to obtain additional equity and/or debt financing, such funding is not assured and may not be available to the Company on favorable or acceptable terms and may involve significant restrictive covenants. Any additional equity financing is also not assured and, if available to the Company, will most likely be dilutive to its current stockholders. If the Company is not able to obtain additional debt or equity financing on a timely basis, the impact on the Company will be material and adverse.
These uncertainties raise substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
9 |
Grant and Contract Revenue
Revenues from grants, contracts, and awards provided by governmental agencies are recorded based upon the terms of the specific agreements, which generally provide that revenue is earned when the allowable costs specified in the applicable agreement have been incurred or a milestone has been met. Cash received from federal grants, contracts, and awards can be subject to audit by the grantor and, if the examination results in a disallowance of any expenditure, repayment could be required.
New Accounting Pronouncements Recently Adopted
In August 2020, the Financial Statement Accounting Board (the “FASB”) issued ASU 2020-06 which simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. For contracts in an entity’s own equity, the new guidance eliminates some of the current requirements for equity classification such as the requirement that settlement in unregistered shares is permitted. In addition, the new guidance reduces the number of accounting models that require separating embedded conversion features from convertible instruments, including eliminating the requirement to recognize a beneficial conversion feature if the conversion feature is in the money and does not require bifurcation as a derivative liability. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. The Company adopted the new standards January 1, 2023. The adoption of this standard allows the Company in the future and, in certain circumstances, to avoid derivative treatment of warrants and avoid beneficial conversion treatment of certain convertible preferred shares.
New Accounting Pronouncements Not Yet Adopted
The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.
Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. The Company had potentially dilutive securities, totaling approximately million and million as of September 30, 2023, and 2022, respectively.
10 |
Effect of | ||||||||||||
Dilutive | ||||||||||||
Basic | Warrant | Diluted | ||||||||||
Calculation | Securities | Calculation | ||||||||||
Numerator: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ||||||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Denominator: | ||||||||||||
Number of shares used in per common share calculations: | ||||||||||||
Net loss per common share: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ||||||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) |
Below are basic and diluted loss per share data for the nine months ended September 30, 2023, which are in thousands except for share and per share data:
Effect of | ||||||||||||
Dilutive | ||||||||||||
Basic | Warrant | Diluted | ||||||||||
Calculation | Securities | Calculation | ||||||||||
Numerator: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ( | ) | ( | ) | ||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Denominator: | ||||||||||||
Number of shares used in per common share calculations: | ||||||||||||
Net loss per common share: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ( | ) | ( | ) | ||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) |
Below are basic and diluted loss per share data for the three months ended September 30, 2022, which are in thousands except for share and per share data:
Basic Calculation | Effect of Dilutive | Diluted Calculation | ||||||||||
Numerator: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ||||||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Denominator: | ||||||||||||
Number of shares used in per common share calculations: | ||||||||||||
Net loss per common share: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ||||||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) |
11 |
Below are basic and diluted loss per share data for the nine months ended September 30, 2022, which are in thousands except for share and per share data:
Basic Calculation | Effect of Dilutive | Diluted Calculation | ||||||||||
Numerator: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ||||||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Denominator: | ||||||||||||
Number of shares used in per common share calculations: | ||||||||||||
Net loss per common share: | ||||||||||||
Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Deemed dividend and accretion of a discount | ||||||||||||
Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) |
3. Inventories
Inventories consisted of the following (in thousands):
September
30, 2023 | December
31, 2022 | |||||||
Raw materials | $ | $ | ||||||
WIP | ||||||||
Finished goods | ||||||||
$ | $ |
As
of September 30, 2023, inventories totaling approximately $
4. Fair Value Measurements
Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis
The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:
Level 1 - | quoted market prices for identical assets or liabilities in active markets. | |
Level 2 - | observable prices that are based on inputs not quoted on active markets but corroborated by market data. | |
Level 3 - | unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. |
The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of September 30, 2023, and December 31, 2022. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2023, and December 31, 2022 (in thousands):
Fair Value Measurements as of September 30, 2023 | ||||||||||||||||
Description | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Derivative liability | ||||||||||||||||
Common stock warrants | $ | $ | $ | $ |
Fair Value Measurements as of December 31, 2022 | ||||||||||||||||
Description | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Derivative liability | ||||||||||||||||
Common stock warrants | $ | $ | $ | $ |
12 |
The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the nine months ended September 30, 2023, and 2022. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2023, and 2022 (in thousands):
Common | ||||
Stock | ||||
Warrants | ||||
Balance as of December 31, 2021 | $ | ( | ) | |
Change in fair value | ||||
Balance as of September 30, 2022 | $ | ( | ) | |
Balance as of December 31, 2022 | $ | ( | ) | |
Issuance of derivatives | ( | ) | ||
Exercise of warrants | ||||
Change in fair value | ||||
Other | ||||
Balance as of September 30, 2023 | $ | ( | ) |
Common Stock Warrants
The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of September 30, 2023, and December 31, 2022, the derivative liability was calculated using the Monte Carlo Simulation valuation.
The assumptions used in estimating the common stock warrant liability using the Monte Carlo simulation valuation model as of September 30, 2023, and December 31, 2022 were as follows:
September
30, 2023 | December
31, 2022 | |||||||
Weighted-average risk-free interest rate | % | % | ||||||
Weighted-average expected life (in years) | ||||||||
Expected dividend yield | % | % | ||||||
Weighted-average expected volatility | % | % |
Other Financial Instruments
The Company’s recorded values of cash and cash equivalents, account and other receivables, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.
5. Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):
September
30, 2023 | December
31, 2022 | |||||||
Payroll and related expense | $ | $ | ||||||
Accrued payables |